P115 Quality-of-life analysis in the randomized phase II CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer
Proceedings article published in 2019 by
T. Callewaert,
A. Vanderstichele,
E. Van Nieuwenhuysen,
S. Han,
N. Concin,
T. Van Gorp 
,
P. Berteloot,
P. Neven,
P. Busschaert,
D. Lambrechts,
I. Vergote
,
P. Berteloot,
P. Neven,
P. Busschaert,
D. Lambrechts,
I. Vergote
